Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.
By F. Saad, Janet E Brown, C. Poznak, T. Ibrahim, S. Stemmer, A. Stopeck, I. Diel, S. Takahashi, N. Shore, D. Henry and 8 more. Annals of Oncology, 2012
627 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/ea954198a99aa5e662a48fecee51d7f0410e4c30
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- T. Dodson
- R. Goodday
- T. Aghaloo
- B. Mehrotra
Citations in the corpus
- Medication-Related Osteonecrosis of the Jaw—2014 Update (2014, background): “Conservative therapy is the mainstay of care and although it may not necessarily lead to complete resolution of lesions, it may symptomatically provide long-term relief.((26,247)) Among patients with breast cancer and multiple myeloma, Fortuna and colleagues((248)) reported a more rapid response to ”
- Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus (2015, neutral): “Conservative therapy is the mainstay of care and although it may not necessarily lead to complete resolution of lesions, it may symptomatically provide long-term relief.((26,247)) Among patients with breast cancer and multiple myeloma, Fortuna and colleagues((248)) reported a more rapid response to ”